Transcatheter arterial chemoembolization combined with tumor necrosis factor for primary hepatic cancer
- Author:
Yu-Tang CHEN
1
Author Information
1. Department of Interventional Therapy
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
DNA, recombinant;
Embolization, therapeutic;
Liver neoplasms;
Tumor necrosis factors
- From:
Tumor
2008;28(2):159-162
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe and compare short-term therapeutic effect and adverse effect of recombinant mutant human tumor necrosis factor (rmhTNF) via transcatheter arterial chemoembolization in the treatment of primary hepatic cancer. Methods: Sixty patients with confirmed primary hepatic cancer in clinic were randomly divided into two groups (n = 30). Group A (therapeutic group) received conventional TACE first and then the catheter was inserted into the hepatic artery and rmhTNF, chemotherapeutic drugs, and hyper liquid iodide oil were emulsified and infused to induce intraarterial embobilization. Group B (control group) received one cycle of conventional TACE and the second cycle of conventional TACE 1 month later. After two cycles of interventional treatment the short-term therapeutic effect and adverse reaction of the two groups were evaluated. Results: Comparison of two groups, the tumor volume were obviously reduced in the therapeutic group. There was significant difference in the short-term therapeutic efficacy (P < 0.05). But the difference had no statistical significance in the injury of liver function (P > 0.05). Some patients experienced shiver after infusion of rmhTNF. Conclusion: TACE combined with rmhTNF is an effective method for primary hepatic cancer with good short-term outcome and no obvious adverse reaction. It is worthy of popularization in clinic.
